{
    "xml": "<topic id=\"PHP1458\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/dalteparin-sodium\" basename=\"dalteparin-sodium\" title=\"DALTEPARIN SODIUM\">\n<title>DALTEPARIN SODIUM</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_226\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/heparins/dalteparin\">Dalteparin</xref>\n</p>\n<data name=\"vtmid\">108986009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_502671253\" title=\"Heparins\">Heparins</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34597\" title=\"HEPARINS\" namespace=\"/drug-classes/heparins\">HEPARINS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP39730\" outputclass=\"unlicensedUse\" rev=\"1.6\" parent=\"/drugs/dalteparin-sodium\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Not licensed for treatment of venous thromboembolism in pregnancy.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39767\" outputclass=\"pregnancy\" parent=\"/drugs/dalteparin-sodium\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Not known to be harmful, low molecular weight heparins do not cross the placenta. Multidose vial contains benzyl alcohol&#8212;manufacturer advises avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39811\" outputclass=\"breastFeeding\" parent=\"/drugs/dalteparin-sodium\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Due to the relatively high molecular weight and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible, however manufacturers advise avoid.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39785\" outputclass=\"hepaticImpairment\" parent=\"/drugs/dalteparin-sodium\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Dose reduction may be required in severe impairment&#8212;risk of bleeding may be increased.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39752\" outputclass=\"renalImpairment\" parent=\"/drugs/dalteparin-sodium\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Risk of bleeding may be increased&#8212;dose reduction may be required. </p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use of unfractionated heparin may be preferable.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39725\" outputclass=\"monitoringRequirements\" parent=\"/drugs/dalteparin-sodium\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"therapeuticDrugMonitoring\">\n<sectiondiv>\n<p>For monitoring during treatment of deep-vein thrombosis and of pulmonary embolism, blood should be taken 3&#8211;4 hours after a dose (recommended plasma concentration of anti-Factor Xa 0.5&#8211;1&#8239;unit/mL); monitoring not required for once-daily treatment regimen and not generally necessary for twice-daily regimen.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Routine monitoring of anti-Factor Xa activity is not usually required during treatment with dalteparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP39713\" outputclass=\"nationalFunding\" rev=\"1.10\" parent=\"/drugs/dalteparin-sodium\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (February 2011) that dalteparin (<i>Fragmin</i>\n<ph outputclass=\"sc\">\n<tm tmtype=\"reg\"/>\n</ph>) is accepted for restricted use within NHS Scotland as extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP1458-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/dalteparin-sodium\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77437\" title=\"Solution for injection\" namespace=\"/drugs/dalteparin-sodium/solution-for-injection\">Solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78403\" namespace=\"/treatment-summaries/venous-thromboembolism\" title=\"Venous thromboembolism\" count=\"1\" rel=\"backlink\">Venous thromboembolism</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78413\" namespace=\"/treatment-summaries/parenteral-anticoagulants\" title=\"Parenteral anticoagulants\" count=\"2\" rel=\"backlink\">Parenteral anticoagulants</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_226\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/heparins/dalteparin\" title=\"Dalteparin\" count=\"1\" rel=\"link\">Dalteparin</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34597\" namespace=\"/drug-classes/heparins\" title=\"HEPARINS\" count=\"1\" rel=\"link\">HEPARINS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77437\" namespace=\"/drugs/dalteparin-sodium/solution-for-injection\" title=\"Solution for injection\" count=\"1\" rel=\"link\">Solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP1458",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/dalteparin-sodium",
    "basename": "dalteparin-sodium",
    "title": "DALTEPARIN SODIUM",
    "interactants": [
        {
            "id": "bnf_int_226",
            "label": "Dalteparin"
        }
    ],
    "vtmid": "108986009",
    "drugClassification": [
        "Heparins"
    ],
    "inheritsFromClass": [
        "HEPARINS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Not licensed for treatment of venous thromboembolism in pregnancy.",
                "html": "<p>Not licensed for treatment of venous thromboembolism in pregnancy.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Not known to be harmful, low molecular weight heparins do not cross the placenta. Multidose vial contains benzyl alcohol&#8212;manufacturer advises avoid.",
                "html": "<p>Not known to be harmful, low molecular weight heparins do not cross the placenta. Multidose vial contains benzyl alcohol&#8212;manufacturer advises avoid.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Due to the relatively high molecular weight and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible, however manufacturers advise avoid.",
                "html": "<p>Due to the relatively high molecular weight and inactivation in the gastro-intestinal tract, passage into breast-milk and absorption by the nursing infant are likely to be negligible, however manufacturers advise avoid.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Dose reduction may be required in severe impairment&#8212;risk of bleeding may be increased.",
                "html": "<p>Dose reduction may be required in severe impairment&#8212;risk of bleeding may be increased.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Risk of bleeding may be increased&#8212;dose reduction may be required.",
                "html": "<p>Risk of bleeding may be increased&#8212;dose reduction may be required. </p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use of unfractionated heparin may be preferable.",
                "html": "<p>Use of unfractionated heparin may be preferable.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "therapeuticDrugMonitoring": [
            {
                "type": "therapeuticDrugMonitoring",
                "textContent": "For monitoring during treatment of deep-vein thrombosis and of pulmonary embolism, blood should be taken 3&#8211;4 hours after a dose (recommended plasma concentration of anti-Factor Xa 0.5&#8211;1 unit/mL); monitoring not required for once-daily treatment regimen and not generally necessary for twice-daily regimen.",
                "html": "<p>For monitoring during treatment of deep-vein thrombosis and of pulmonary embolism, blood should be taken 3&#8211;4 hours after a dose (recommended plasma concentration of anti-Factor Xa 0.5&#8211;1&#8239;unit/mL); monitoring not required for once-daily treatment regimen and not generally necessary for twice-daily regimen.</p>"
            }
        ],
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Routine monitoring of anti-Factor Xa activity is not usually required during treatment with dalteparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).",
                "html": "<p>Routine monitoring of anti-Factor Xa activity is not usually required during treatment with dalteparin, but may be necessary in patients at increased risk of bleeding (e.g. in renal impairment and those who are underweight or overweight).</p>"
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (February 2011) that dalteparin (Fragmin ) is accepted for restricted use within NHS Scotland as extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (February 2011) that dalteparin (<i>Fragmin</i> <ph outputclass=\"sc\"> <tm tmtype=\"reg\"/> </ph>) is accepted for restricted use within NHS Scotland as extended treatment of symptomatic venous thromboembolism and prevention of its recurrence in patients with solid tumours.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77437",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78403",
                "label": "Venous thromboembolism",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78413",
                "label": "Parenteral anticoagulants",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_226",
                "label": "Dalteparin",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34597",
                "label": "HEPARINS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77437",
                "label": "Solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}